KR101753655B1 - Composition for sunscreen - Google Patents
Composition for sunscreen Download PDFInfo
- Publication number
- KR101753655B1 KR101753655B1 KR1020100116411A KR20100116411A KR101753655B1 KR 101753655 B1 KR101753655 B1 KR 101753655B1 KR 1020100116411 A KR1020100116411 A KR 1020100116411A KR 20100116411 A KR20100116411 A KR 20100116411A KR 101753655 B1 KR101753655 B1 KR 101753655B1
- Authority
- KR
- South Korea
- Prior art keywords
- derivative
- composition
- salicylate
- cinnamate
- sunscreen
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 230000000475 sunscreen effect Effects 0.000 title abstract description 29
- 239000000516 sunscreening agent Substances 0.000 title abstract description 28
- 150000001851 cinnamic acid derivatives Chemical class 0.000 claims abstract description 15
- UGRXGEHQNPBILJ-UHFFFAOYSA-N (2-methoxyphenyl) prop-2-enoate Chemical class COC1=CC=CC=C1OC(=O)C=C UGRXGEHQNPBILJ-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 230000003287 optical effect Effects 0.000 claims abstract description 4
- 230000004224 protection Effects 0.000 claims abstract description 4
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 claims description 27
- 229960000601 octocrylene Drugs 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 18
- XVAMCHGMPYWHNL-UHFFFAOYSA-N bemotrizinol Chemical group OC1=CC(OCC(CC)CCCC)=CC=C1C1=NC(C=2C=CC(OC)=CC=2)=NC(C=2C(=CC(OCC(CC)CCCC)=CC=2)O)=N1 XVAMCHGMPYWHNL-UHFFFAOYSA-N 0.000 claims description 14
- UBNYRXMKIIGMKK-RMKNXTFCSA-N amiloxate Chemical compound COC1=CC=C(\C=C\C(=O)OCCC(C)C)C=C1 UBNYRXMKIIGMKK-RMKNXTFCSA-N 0.000 claims description 10
- 150000003918 triazines Chemical class 0.000 claims description 9
- FMRHJJZUHUTGKE-UHFFFAOYSA-N Ethylhexyl salicylate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1O FMRHJJZUHUTGKE-UHFFFAOYSA-N 0.000 claims description 8
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 claims description 8
- -1 isopentyl methoxy Chemical group 0.000 claims description 8
- WAJCJDLRJVDSSD-UHFFFAOYSA-N 2-ethylhexyl 2-cyano-3-(4-methoxyphenyl)-3-phenylprop-2-enoate Chemical group C=1C=C(OC)C=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 WAJCJDLRJVDSSD-UHFFFAOYSA-N 0.000 claims description 7
- 150000003872 salicylic acid derivatives Chemical class 0.000 claims description 7
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 claims description 6
- ISDGWTZFJKFKMO-UHFFFAOYSA-N 2-phenyl-1,3-dioxane-4,6-dione Chemical class O1C(=O)CC(=O)OC1C1=CC=CC=C1 ISDGWTZFJKFKMO-UHFFFAOYSA-N 0.000 claims description 6
- 229940114081 cinnamate Drugs 0.000 claims description 6
- 229940073668 ethylhexyl methoxycrylene Drugs 0.000 claims description 6
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 claims description 6
- 239000002981 blocking agent Substances 0.000 claims description 5
- 229960004881 homosalate Drugs 0.000 claims description 5
- 229960001679 octinoxate Drugs 0.000 claims description 5
- PDHSAQOQVUXZGQ-JKSUJKDBSA-N (2r,3s)-2-(3,4-dihydroxyphenyl)-3-methoxy-3,4-dihydro-2h-chromene-5,7-diol Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2OC)=CC=C(O)C(O)=C1 PDHSAQOQVUXZGQ-JKSUJKDBSA-N 0.000 claims description 4
- NWGAAWUUGRXXSC-UHFFFAOYSA-N 1-(2-hydroxypropoxy)propan-2-yl 2-hydroxybenzoate Chemical compound CC(O)COCC(C)OC(=O)C1=CC=CC=C1O NWGAAWUUGRXXSC-UHFFFAOYSA-N 0.000 claims description 4
- KBKGPMDADJLBEM-UHFFFAOYSA-N 1-(4-pentylphenyl)ethanone Chemical compound CCCCCC1=CC=C(C(C)=O)C=C1 KBKGPMDADJLBEM-UHFFFAOYSA-N 0.000 claims description 4
- AAULBTMMUMJTHW-UHFFFAOYSA-N N1=NN=CC=C1.C(C(C)C)C=1C(=C(C(=C(C(=O)O)C(=O)O)N)C=CC1)CC(C)C.C(C(C)C)C=1C(=C(C(=C(C(=O)O)C(=O)O)N)C=CC1)CC(C)C.C(C(C)C)C=1C(=C(C(=C(C(=O)O)C(=O)O)N)C=CC1)CC(C)C Chemical compound N1=NN=CC=C1.C(C(C)C)C=1C(=C(C(=C(C(=O)O)C(=O)O)N)C=CC1)CC(C)C.C(C(C)C)C=1C(=C(C(=C(C(=O)O)C(=O)O)N)C=CC1)CC(C)C.C(C(C)C)C=1C(=C(C(=C(C(=O)O)C(=O)O)N)C=CC1)CC(C)C AAULBTMMUMJTHW-UHFFFAOYSA-N 0.000 claims description 4
- AALXZHPCKJILAZ-UHFFFAOYSA-N (4-propan-2-ylphenyl)methyl 2-hydroxybenzoate Chemical compound C1=CC(C(C)C)=CC=C1COC(=O)C1=CC=CC=C1O AALXZHPCKJILAZ-UHFFFAOYSA-N 0.000 claims description 3
- JPWUIQIFCDAWQX-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-ethylhexanoate Chemical compound CCCCC(CC)C(=O)OCC(O)CO JPWUIQIFCDAWQX-UHFFFAOYSA-N 0.000 claims description 3
- 125000001891 dimethoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 229960003921 octisalate Drugs 0.000 claims description 3
- XATKDVHSLQMHSY-RMKNXTFCSA-N propan-2-yl (e)-3-(4-methoxyphenyl)prop-2-enoate Chemical compound COC1=CC=C(\C=C\C(=O)OC(C)C)C=C1 XATKDVHSLQMHSY-RMKNXTFCSA-N 0.000 claims description 3
- WMJBVALTYVXGHW-UHFFFAOYSA-N 3,3-diphenylprop-2-enoic acid Chemical class C=1C=CC=CC=1C(=CC(=O)O)C1=CC=CC=C1 WMJBVALTYVXGHW-UHFFFAOYSA-N 0.000 claims description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims description 2
- PVWXTVUZGJXFJQ-CCEZHUSRSA-N methyl (E)-4-methyl-3-phenyl-2-propan-2-ylpent-2-enoate Chemical compound COC(=O)C(\C(C)C)=C(/C(C)C)C1=CC=CC=C1 PVWXTVUZGJXFJQ-CCEZHUSRSA-N 0.000 claims description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims 2
- JFUNRFXFBHNUSB-UHFFFAOYSA-N 3-methoxy-2-phenylprop-2-enoic acid Chemical class COC=C(C(O)=O)C1=CC=CC=C1 JFUNRFXFBHNUSB-UHFFFAOYSA-N 0.000 claims 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 5
- 238000002144 chemical decomposition reaction Methods 0.000 abstract description 3
- 230000000052 comparative effect Effects 0.000 description 28
- 210000003491 skin Anatomy 0.000 description 18
- 239000002537 cosmetic Substances 0.000 description 14
- RMFFCSRJWUBPBJ-UHFFFAOYSA-N 15-hydroxypentadecyl benzoate Chemical compound OCCCCCCCCCCCCCCCOC(=O)C1=CC=CC=C1 RMFFCSRJWUBPBJ-UHFFFAOYSA-N 0.000 description 10
- 229960004101 bemotrizinol Drugs 0.000 description 10
- 239000006071 cream Substances 0.000 description 10
- 239000006210 lotion Substances 0.000 description 9
- 239000000499 gel Substances 0.000 description 8
- 210000004209 hair Anatomy 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229940039717 lanolin Drugs 0.000 description 3
- 235000019388 lanolin Nutrition 0.000 description 3
- 229920002282 polysilicones-15 Polymers 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- IAJNXBNRYMEYAZ-UHFFFAOYSA-N ethyl 2-cyano-3,3-diphenylprop-2-enoate Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC)C1=CC=CC=C1 IAJNXBNRYMEYAZ-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000006201 parenteral dosage form Substances 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000003711 photoprotective effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229940100498 polysilicone-15 Drugs 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical class C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- LFNCNUJTQZONPX-UHFFFAOYSA-N 2-[1-[4-amino-2-(2-methylpropyl)phenyl]-3-methylbutylidene]propanedioic acid;1,3,5-triazine Chemical compound C1=NC=NC=N1.CC(C)CC(=C(C(O)=O)C(O)=O)C1=CC=C(N)C=C1CC(C)C LFNCNUJTQZONPX-UHFFFAOYSA-N 0.000 description 1
- KXTAOXNYQGASTA-UHFFFAOYSA-N 2-benzylidenepropanedioic acid Chemical compound OC(=O)C(C(O)=O)=CC1=CC=CC=C1 KXTAOXNYQGASTA-UHFFFAOYSA-N 0.000 description 1
- ZUYVPAKYYMBQBT-UHFFFAOYSA-N 3,4-diethyl-2-hexoxyphenol Chemical compound CCCCCCOC1=C(O)C=CC(CC)=C1CC ZUYVPAKYYMBQBT-UHFFFAOYSA-N 0.000 description 1
- XPSXNFUPMKXMLB-UHFFFAOYSA-N 3-ethyl-2-hexoxyphenol;5-methoxy-4-phenyltriazine Chemical compound COC1=CN=NN=C1C1=CC=CC=C1.CCCCCCOC1=C(O)C=CC=C1CC XPSXNFUPMKXMLB-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical class NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002535 acidifier Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960002709 amiloxate Drugs 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- YEAYGXLRPMKZBP-KQGICBIGSA-N bis(2-hydroxyethyl)azanium;(e)-3-(4-methoxyphenyl)prop-2-enoate Chemical compound OCCNCCO.COC1=CC=C(\C=C\C(O)=O)C=C1 YEAYGXLRPMKZBP-KQGICBIGSA-N 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- CCRCUPLGCSFEDV-UHFFFAOYSA-N cinnamic acid methyl ester Natural products COC(=O)C=CC1=CC=CC=C1 CCRCUPLGCSFEDV-UHFFFAOYSA-N 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- NZZIMKJIVMHWJC-UHFFFAOYSA-N dibenzoylmethane Chemical class C=1C=CC=CC=1C(=O)CC(=O)C1=CC=CC=C1 NZZIMKJIVMHWJC-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940056211 paraffin Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001699 photocatalysis Effects 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229910021420 polycrystalline silicon Inorganic materials 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920005591 polysilicon Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960002171 tiocarlide Drugs 0.000 description 1
- UEVAMYPIMMOEFW-UHFFFAOYSA-N trolamine salicylate Chemical compound OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O UEVAMYPIMMOEFW-UHFFFAOYSA-N 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4966—Triazines or their condensed derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
본 발명의 유효성분으로서 신남산 유도체, 메톡시페닐아크릴레이트 유도체 및 β,β-디페닐아크릴레이트 유도체를 포함하는 선스크린용 조성물은 광 조사시에 화학적 분해가 현저히 감소되어 광안정성(photo-stability)이 향상되고 활성이 상승되므로 광보호성이 우수하다.The composition for sunscreen comprising a cinnamic acid derivative, a methoxyphenyl acrylate derivative and a?,? - diphenylacrylate derivative as an active ingredient of the present invention has a remarkably reduced chemical decomposition upon photoirradiation, ) Is improved and the activity is increased, so that the optical protection property is excellent.
Description
본 발명은 선스크린용 조성물에 관한 것으로, 보다 구체적으로 광안정성(photo-stability)이 향상되어 광보호성이 우수한 신남산 유도체, 메톡시페닐아크릴레이트 유도체 및 β,β-디페닐아크릴레이트 유도체를 포함하는 선스크린용 조성물에 관한 것이다.
More particularly, the present invention relates to a composition for a sunscreen, and more particularly, to a composition for a sunscreen which comprises a cinnamic acid derivative, a methoxyphenyl acrylate derivative and a?,? -Diphenylacrylate derivative To a composition for a sunscreen.
290nm 내지 400nm 파장의 광 조사는 인간 피부를 붉은 색 또는 갈색으로 변화시킬 수 있으며, 특히 UVB(290 내지 320nm 파장)의 조사는 홍반(erythemas) 및 피부화상을 유발한다고 알려져 있다. 또한, 피부의 태닝을 유발하는 UVA(320 내지 400nm 파장)는 특히 민감성 피부 또는 연속적으로 태양광 조사에 노출된 피부에 해로운 변화를 초래할 수 있다. 또한 UVA 조사는 피부 탄력성의 손실 및 주름의 발생을 유발하여, 결과적으로 피부를 노화시킨다. 심지어 광독성 또는 광알레르기성 반응의 원인이 될 수도 있다. 피부 천연 탄력성의 유지와 같은 미용적 및 화장학적 이유 및 노화와 질병 유발의 이유로 인하여, UVA가 피부에 일으키는 부작용을 방어하기 위한 태양광 차단에 대한 요구가 점점 증가하고 있다. Light irradiation at wavelengths of 290 nm to 400 nm can change human skin to red or brown, and irradiation with UVB (290 to 320 nm wavelength) in particular is known to cause erythemas and skin burns. In addition, UVA (320-400 nm wavelength), which causes skin tanning, can lead to deleterious changes, especially to sensitive skin or to skin exposed continuously to sunlight. UVA irradiation also causes the loss of skin elasticity and the occurrence of wrinkles, resulting in aging of the skin. It may even cause phototoxicity or photoallergic reactions. Due to cosmetic and cosmetic reasons such as the maintenance of natural elasticity of the skin and reasons of aging and disease induction, there is an increasing demand for sunscreening to protect the skin from side effects caused by UVA.
현재 피부 및 모발을 보호할 목적으로 일반적으로 사용되는 UVB 차단제군은, 고도의 고유 흡수력을 나타내는 화합물인 신남산 유도체, 특히 2-에틸헥실 p-메톡시신나메이트 또는 이소아밀 p-메톡시신나메이트로 구성된다. Currently, a group of UVB blockers commonly used for the purpose of protecting skin and hair is a derivative of cinnamic acid, which is a compound exhibiting a high inherent absorption power, especially 2-ethylhexyl p-methoxy cinnamate or isoamyl p-methoxy cinnamate .
신남산 유도체는 특정 조건하에서, 특히 이들이 UV 조사에 노출되는 경우 화학적으로 분해된다는 단점이 있다. 이러한 분해가 일어나는 경우, 신남산으로부터 유도된 상기 활성성분은 그 활성 특성을 상실한다. 그 결과 더 이상 지속적인 피부 및 모발의 광범위한 태양광 차단 효과를 나타내지 않는다.
Derivatives of cinnamic acid have the disadvantage that they decompose chemically under certain conditions, especially when they are exposed to UV radiation. When such degradation occurs, the active ingredient derived from cinnamic acid loses its activity properties. As a result, they no longer exhibit the broadest sunscreen effect of continuous skin and hair.
본 발명은 광안정성(photo-stability)이 향상되어 광조사시 화학적 분해가 현저히 감소됨으로써 활성을 유지하여 광보호성이 우수한 신남산 유도체, 메톡시페닐아크릴레이트 유도체 및 β,β-디페닐아크릴레이트 유도체를 포함하는 선스크린용 조성물을 제공하는 것을 그 목적으로 한다.
The present invention relates to a photopolymerizable composition containing a cinnamic acid derivative, a methoxyphenyl acrylate derivative, and a photopolymerization initiator having a photo-stability and a photocatalytic activity, It is an object of the present invention to provide a composition for a sunscreen containing a derivative.
상기와 같은 목적을 해결하기 위하여 본 발명은 유효성분으로서 신남산 유도체, 메톡시페닐아크릴레이트 유도체 및 β,β-디페닐아크릴레이트 유도체를 포함하는 선스크린용 조성물을 제공한다.
In order to solve the above-mentioned problems, the present invention provides a composition for sunscreen comprising a cinnamic acid derivative, a methoxyphenyl acrylate derivative and a?,? - diphenylacrylate derivative as an active ingredient.
본 발명의 일실시예에 있어서, 상기 메톡시페닐아크릴레이트 유도체는 에틸헥실메톡시크릴렌일 수 있다.
In one embodiment of the present invention, the methoxyphenyl acrylate derivative may be ethylhexylmethoxycrylene.
본 발명의 일실시예에 있어서, 상기 β,β-디페닐아크릴레이트 유도체는 옥토크릴렌 또는 에토크릴렌, 또는 그 둘 다일 수 있다.
In one embodiment of the present invention, the beta, beta -diphenylacrylate derivative may be octocrylene or ethocrylene, or both.
본 발명의 일실시예에 있어서, 상기 조성물은 트리아진 유도체를 더 포함할 수 있다.
In one embodiment of the present invention, the composition may further comprise a triazine derivative.
본 발명의 일실시예에 있어서, 상기 조성물은 살리실산 유도체를 더 포함할 수 있다.
In one embodiment of the present invention, the composition may further comprise a salicylic acid derivative.
본 발명의 일실시예에 있어서, 상기 조성물은 벤잘말로네이트 유도체를 더 포함할 수 있다.
In one embodiment of the present invention, the composition may further comprise a benzal malonate derivative.
본 발명의 일실시예에 있어서, 상기 신남산 유도체는 2-에틸헥실 p-메톡시신나메이트, 이소아밀 p-메톡시신나메이트, 이소프로필 메톡시신나메이트, 이소펜틸 메톡시신나메이트, 디이소프로필 메틸신나메이트, 디에탄올아민 메톡시신나메이트, 시녹세이트 및 글리세릴 에틸헥사노에이트 디메톡시신나메이트로 이루어진 군으로부터 선택되는 하나 이상인 것일 수 있다.
In one embodiment of the present invention, the cinnamic acid derivative is selected from the group consisting of 2-ethylhexyl p-methoxy cinnamate, isoamyl p-methoxy cinnamate, isopropyl methoxy cinnamate, isopentyl methoxy cinnamate, Propyl methyl cinnamate, diethanol amine methoxy cinnamate, cyoxate, and glyceryl ethyl hexanoate dimethoxy cinnamate.
본 발명의 일실시예에 있어서, 상기 트리아진 유도체는 비스-에틸헥실옥시페놀메톡시페닐트리아진 또는 트리스(디이소부틸-아미노벤잘말로네이트)트리아진, 또는 그 둘 다일 수 있다.
In one embodiment of the present invention, the triazine derivative may be bis-ethylhexyloxyphenol methoxyphenyltriazine or tris (diisobutyl-aminobenzalmalonate) triazine, or both.
본 발명의 일실시예에 있어서, 상기 살리실산 유도체는 2-에틸헥실 살리실레이트, 호모멘틸 살리실레이트, 트리에탄올아민 살리실레이트, 이소프로필벤질 살리실레이트, 디프로필렌글리콜 살리실레이트 및 옥틸 살리실레이트로 이루어진 군으로부터 하나 이상 선택되는 것일 수 있다.
In one embodiment of the present invention, the salicylic acid derivative is selected from the group consisting of 2-ethylhexyl salicylate, homomenthyl salicylate, triethanolamine salicylate, isopropylbenzyl salicylate, dipropylene glycol salicylate and octyl salicylate ≪ RTI ID = 0.0 > and / or < / RTI >
본 발명의 일실시예에 있어서, 상기 벤잘말로네이트 유도체는 폴리실리콘-15일 수 있다.
In one embodiment of the present invention, the benzal malonate derivative may be polysilicon-15.
본 발명의 일실시예에 있어서, 상기 조성물은 UV-A, UV-B, 또는 UV-A 및 UV-B에 활성인 부가의 친수성 또는 친유성 광차단제를 추가로 함유하는 것일 수 있다.
In one embodiment of the present invention, the composition may further comprise UV-A, UV-B, or additional hydrophilic or lipophilic light blocking agents that are active in UV-A and UV-B.
본 발명의 신남산 유도체, 메톡시페닐아크릴레이트 유도체 및 β,β-디페닐아크릴레이트 유도체를 포함하는 선스크린용 조성물은 광 조사시에 화학적 분해가 현저히 감소되어 광안정성(photo-stability)이 향상되고 활성이 상승되므로 광보호성이 우수하다.
The composition for a sunscreen comprising a cinnamic acid derivative, a methoxyphenyl acrylate derivative, and a β, β-diphenyl acrylate derivative of the present invention has a remarkably reduced chemical decomposition at the time of light irradiation, thereby improving the photo-stability And the activity is increased, so that the optical protection is excellent.
이하에서는, 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 본 발명을 용이하게 실시할 수 있도록 하기 위하여, 본 발명의 바람직한 실시예들에 관하여 상세히 설명하기로 한다.
Hereinafter, preferred embodiments of the present invention will be described in detail in order to facilitate the present invention by those skilled in the art.
본 발명은 유효성분으로서 신남산 유도체, 메톡시페닐아크릴레이트 유도체 및 β,β-디페닐아크릴레이트 유도체를 포함하는 선스크린용 조성물을 제공한다.
The present invention provides a composition for sunscreen comprising a cinnamic acid derivative, a methoxyphenyl acrylate derivative and a?,? - diphenylacrylate derivative as an active ingredient.
상기 신남산 유도체는 2-에틸헥실 p-메톡시신나메이트, 이소아밀 p-메톡시신나메이트, 이소프로필 메톡시신나메이트, 이소펜틸 메톡시신나메이트, 디이소프로필 메틸신나메이트, 디에탄올아민 메톡시신나메이트, 시녹세이트 및 글리세릴 에틸헥사노에이트 디메톡시신나메이트로 이루어진 군으로부터 하나 이상 선택되는 것일 수 있고, 더욱 바람직하게는 2-에틸헥실 p-메톡시신나메이트, 이소아밀 p-메톡시신나메이트일 수 있다. 그러나 반드시 이에 한정되는 것은 아니다. 상기 에틸헥실 메톡시신나메이트는 Hoffman-LaRoche社가 상표명 'Parsol MCX'로 판매하고, 상기 이소아밀 메톡시신나메이트는 Haarmann and Reimer社가 상표명 'Neo Heliopan E 1000'으로 판매한다.
The cinnamic acid derivatives include 2-ethylhexyl p-methoxy cinnamate, isoamyl p-methoxy cinnamate, isopropyl methoxy cinnamate, isopentyl methoxy cinnamate, diisopropyl methyl cinnamate, diethanolamine meth Methoxy cinnamate, isoxyl cinnamate, cyoxate and glyceryl ethylhexanoate dimethoxy cinnamate, more preferably 2-ethylhexyl p-methoxy cinnamate, isoamyl p-methoxy It can be cinnamate. However, the present invention is not limited thereto. The ethylhexylmethoxycinnamate is sold under the trade name 'Parsol MCX' by Hoffman-LaRoche and the isoamyl methoxycinnamate is sold under the trade name 'Neo Heliopan E 1000' by Haarmann and Reimer.
또한, 상기 메톡시페닐아크릴레이트 유도체는 에틸헥실메톡시크릴렌일 수 있으나, 반드시 이에 한정되는 것은 아니다. 상기 에틸헥실메톡시크릴렌은 Hallstar社가 상표명 'Solastay S1'으로 판매한다.
In addition, the methoxyphenyl acrylate derivative may be ethylhexylmethoxycrylene, but is not limited thereto. The ethylhexylmethoxycrylene is sold under the trade name 'Solastay S1' by Hallstar.
또한, 상기 β,β-디페닐아크릴레이트 유도체는 옥토크릴렌 또는 에토크릴렌, 또는 그 둘 다일 수 있고, 더욱 바람직하게는 옥토크릴렌일 수 있다. 옥토크릴렌은 BASF社가 상표명 'Uvinul N539'로 판매하고, 상기 에토크릴렌은 BASF 社가 상표명 'Uvinul N35'로 판매한다.
Further, the?,? - diphenylacrylate derivative may be octocrylene or ethocrylene, or both, more preferably octocrylene. Octocrylene is sold by BASF under the trade designation 'Uvinul N539', and the etocrylene is sold under the trade designation 'Uvinul N35' by BASF.
이에 더하여, 본 발명의 일실시예에 따른 선스크린용 조성물은 트리아진 유도체를 더 포함할 수 있다. 상기 트리아진 유도체는 비스-에틸헥실옥시페놀메톡시페닐트리아진 또는 트리스(디이소부틸-아미노벤잘말로네이트)-트리아진, 또는 그 둘 다일 수 있고, 더욱 바람직하게는 비스-에틸헥실옥시페놀메톡시페닐트리아진일 수 있다. 상기 비스-에틸헥실옥시페놀메톡시페닐트리아진은 Ciba Specialty Chemicals社가 상표명 'Tinosorb S'로 판매하는 아니소트리아진이다. 또한 상기 트리스(디이소부틸-아미노벤잘말로네이트)-트리아진은 더 구체적으로는 2,4,6-트리스(디이소부틸 4'-아미노벤잘말로네이트)-s-트리아진일 수 있다.
In addition, the composition for a sun screen according to an embodiment of the present invention may further include a triazine derivative. The triazine derivative may be bis-ethylhexyloxyphenol methoxyphenyltriazine or tris (diisobutyl-aminobenzalmalonate) -triazine, or both, and more preferably bis-ethylhexyloxyphenol Lt; / RTI > The bis-ethylhexyloxyphenol methoxyphenyltriazine is an anotriazine available under the trade designation "Tinosorb S" from Ciba Specialty Chemicals. The tris (diisobutyl-aminobenzalmalonate) -triazine can be more specifically 2,4,6-tris (diisobutyl 4'-aminobenzalmalonate) -s-triazine.
또한, 본 발명의 일시예에 따른 선스크린용 조성물은 살리실산 유도체를 더 포함할 수 있다. 상기 살리실산 유도체는 2-에틸헥실 살리실레이트, 호모멘틸 살리실레이트, 트리에탄올아민 살리실레이트, 이소프로필벤질 살리실레이트, 디프로필렌글리콜 살리실레이트 및 옥틸 살리실레이트로 이루어진 군으로부터 하나 이상 선택되는 것일 수 있으나, 반드시 이에 한정되는 것은 아니다. 상기 호모멘틸 살리실레이트는 호모살레이트로도 명명되며, Rona/EM Industries社가 명칭 'Eusolex HMS'로 판매한다. 상기 2-에틸헥실 살리실레이트는 Haarmann and Reimer社가 명칭 'Neo Heliopan OS'로 판매하며, 상기 디프로필렌글리콜 살리실레이트는 Scher社가 명칭 'Dipsal'로 판매한다. 또한 상기 트리에탄올아민 살리실레이트는 Haarmann and Reimer가 상표명 'Neo Heliopan TS'로 판매한다.
The composition for sunscreen according to one embodiment of the present invention may further include a salicylic acid derivative. Wherein the salicylic acid derivative is at least one selected from the group consisting of 2-ethylhexyl salicylate, homomenthyl salicylate, triethanolamine salicylate, isopropylbenzyl salicylate, dipropylene glycol salicylate and octyl salicylate But is not limited thereto. The homomenthyl salicylate is also referred to as homosalate and sold under the name 'Eusolex HMS' by Rona / EM Industries. The 2-ethylhexyl salicylate is sold under the name 'Neo Heliopan OS' by Haarmann and Reimer, and the dipropylene glycol salicylate is sold under the name 'Dipsal' by Scher. The triethanolamine salicylate is also marketed under the trade name " Neo Heliopan TS " by Haarmann and Reimer.
또한, 본 발명의 일실시예에 따른 선스크린용 조성물은 벤잘말로네이트 유도체를 더 포함할 수 있고, 바람직하게는 폴리실리콘-15을 더 포함할 수 있다. 폴리실리콘-15는 DSM社가 상표명 'Parsol SLX'로 판매하는, 벤잘말로네이트 작용기를 갖는 폴리오르가노실록산으로, 디메티코디에틸 벤잘말로네이트(Dimethicodiethyl benzalmalonate)로 명명되기도 한다.
In addition, the composition for sunscreen according to an embodiment of the present invention may further include a benzal malonate derivative, and may further include polysilicon-15. Polysilicon-15 is a polyorganosiloxane with a benzal malonate functionality marketed by DSM under the trade designation 'Parsol SLX' and may also be named dimethicodiethyl benzalmalonate.
본 발명의 선스크린용 조성물은, 상기의 모든 성분을 제외하고, UV-A, UV-B, 또는 UV-A 및 UV-B에 활성인 부가의 친수성 또는 친유성 광차단제를 추가로 함유할 수 있다. 상기 부가의 광차단제는 캠퍼 유도체, 벤조페논 유도체, 디벤조일메탄 유도체, p-아미노벤조산 유도체 또는 중합체 차단제, 및 벤조트리아졸 관능기를 갖는 규소 유도체가 아닌 실리콘 차단제로부터 선택되는 것일 수 있으나, 반드시 이에 한정되는 것은 아니다.
The compositions for sunscreens of the present invention may additionally contain additional hydrophilic or lipophilic light blocking agents that are active in UV-A, UV-B, or UV-A and UV-B, have. The additional light blocking agent may be selected from a camphor derivative, a benzophenone derivative, a dibenzoylmethane derivative, a p-aminobenzoic acid derivative or a polymer blocker, and a silicone blocker not a silicon derivative having a benzotriazole functional group, It is not.
본 발명에 따른 선스크린용 조성물은 예를 들어, 약학 조성물 또는 화장료 조성물일 수 있다.
The composition for sunscreen according to the present invention may be, for example, a pharmaceutical composition or a cosmetic composition.
상기 선스크린용 약학 조성물에는 방부제, 안정화제, 수화제 또는 유화 촉진제, 삼투압 조절을 위한 염 및/또는 완충제 등의 약제학적 보조제 및 기타 치료적으로 유용한 물질을 추가로 함유할 수 있으며, 통상적인 방법에 따라 다양한 비경구 투여 형태로 제형화할 수 있다. 비경구 투여 형태로 경피 투여형 제형일 수 있으며, 예를 들어 로션, 연고, 겔, 크림, 패취 또는 분무제 제형일 수 있으나, 이에 제한되는 것은 아니다.The pharmaceutical composition for sunscreen may further contain a preservative, a stabilizer, a wetting agent or an emulsifying accelerator, a pharmaceutical adjuvant such as a salt and / or a buffer for controlling osmotic pressure, and other therapeutically useful substances, And can be formulated into various parenteral dosage forms accordingly. Parenteral dosage forms, and may be, for example, but not limited to lotions, ointments, gels, creams, patches or spray formulations.
상기 유효 성분의 투여량 결정은 당업자의 수준 내에 있으며, 약물의 1일 투여 용량은 투여하고자 하는 대상의 미만 진행 정도, 발병 시기, 연령, 건강상태, 합병증 등의 다양한 요인에 따라 달라지지만, 성인을 기준으로 할 때 일반적으로는 상기 조성물 1㎍/kg 내지 200mg/kg, 바람직하게는 50㎍/kg 내지 50mg/kg을 1일 1 내지 3회 분할하여 투여할 수 있으며, 상기 투여량은 어떠한 방법으로도 본 발명의 범위를 한정하는 것이 아니다.
The dosage of the active ingredient is within the level of those skilled in the art, and the daily dose of the drug depends on various factors such as the degree of progress of the subject to be administered, the age of onset, age, health condition, As a standard, it is generally possible to administer the composition at a dose of 1 / / kg to 200 mg / kg, preferably 50 / / kg to 50 mg / kg, once or twice a day, Are not intended to limit the scope of the present invention.
상기 선스크린용 화장료 조성물은 제형이 특별히 한정되지 않으며, 목적하는 바에 따라 적절히 선택할 수 있다. 예를 들어, 유연화장수(스킨로션 및 밀크로션), 영양화장수, 에센스, 영양크림, 마사지크림, 팩, 젤, 에센스, 아이크림, 아이에센스, 클렌징크림, 클렌징폼, 클렌징워터, 팩, 파우더, 보디로션, 보디크림, 보디오일 및 보디 에센스로 이루어진 군으로부터 선택된 어느 하나 이상의 제형으로 제조될 수 있으나, 이에 제한되는 것은 아니다.The formulation of the cosmetic composition for sunscreen is not particularly limited and may be appropriately selected according to the purpose. For example, it can be applied to softeners (skin lotion and milk lotion), nutrition lotion, essence, nutrition cream, massage cream, pack, gel, essence, eye cream, eye essence, cleansing cream, cleansing foam, cleansing water, A body lotion, a body cream, a body oil, and a body essence, but the present invention is not limited thereto.
상기 유효 성분의 함량은 특별히 제한되지 않으나, 조성물 총 중량을 기준으로 0.01 내지 20 중량%로 포함될 수 있다. 상기 유효 성분이 상기 함량을 만족하는 경우 부작용 없이 우수한 효능을 나타낼 수 있다.The content of the active ingredient is not particularly limited, but may be 0.01 to 20% by weight based on the total weight of the composition. When the active ingredient satisfies the above content, it can exhibit excellent efficacy without side effects.
상기 선스크린용 화장료 조성물은 또한 조성물이 피부에 도포될 때 분포되기 용이하도록, 희석제, 분산제 또는 담체로서 작용하는 화장용으로 허용 가능한 부형제를 포함할 수 있다. 바람직하게는, 조성물은 수중유형(oil-in-water, O/W) 유화액이고, 유화액은 바람직하게는 물을 부형제의 80 중량% 이상으로 함유한다. 그러나 이에 한정되는 것은 아니며, 공지의 화장용으로 허용 가능한 부형제이면 어느 것이라도 사용 가능하다. The cosmetic composition for sunscreen may also contain a cosmetically acceptable excipient which acts as a diluent, dispersant or carrier so as to facilitate distribution of the composition when applied to the skin. Preferably, the composition is an oil-in-water (O / W) emulsion, and the emulsion preferably contains water in an amount of at least 80% by weight of the excipient. However, the present invention is not limited thereto, and any known excipient for cosmetics may be used.
또한, 상기 선스크린용 화장료 조성물은 본 발명의 분야에서 통상 사용되는 화장 보조제들, 이를테면 지방물질, 유기용매, 규소, 농후제, 연화제, 보충적인 태양광선 차단제, 발포억제제, 보습제, 향료, 보존제, 표면활성제, 총전재, 봉쇄제, 양이온성, 음이온성, 비이온성 혹은 양쪽성 중합체들 또는 그것들의 혼합물, 추진제, 염기화 작용제 또는 산성화 작용제, 염료, 안료 혹은 나노안료(nanopigment) (특히, 자외선조사를 물리적으로 차단시킴으로써 광보호 효과를 보충적으로 제공할 수 있도록 만들어진 것), 또는 화장품에서 통상 사용되는, 특히 태양 광선 차단조성물의 제조에 사용되는 기타 여러 가지 성분들을 포함할 수 있다.In addition, the cosmetic composition for sunscreen can be used as cosmetic auxiliaries commonly used in the field of the present invention such as lipids, organic solvents, silicones, thickeners, softeners, supplementary sunlight blocking agents, foam inhibitors, moisturizers, But are not limited to, surface active agents, antistatic agents, sequestering agents, cationic, anionic, nonionic or ampholytic polymers or mixtures thereof, propellants, basic or acidifying agents, dyes, pigments or nanopigments To provide a photoprotective effect by physically blocking it), or various other ingredients commonly used in cosmetics, especially those used in the manufacture of sunscreen compositions.
유기용매들 중에서는, 저급알코올 및 폴리올, 이를테면 에탄올, 이소프로판올, 프로필렌글리콜, 글리세롤 및 솔비톨 등이 언급될 수 있다.Among the organic solvents, lower alcohols and polyols, such as ethanol, isopropanol, propylene glycol, glycerol, sorbitol and the like can be mentioned.
지방물질은 오일이나 왁스 또는 그것들의 혼합물, 지방산, 지방산에스테르, 지방알코올, 페트롤라텀, 파라핀, 라놀린, 수소화라놀린 또는 아세틸화라놀린으로 구성될 수 있다. 오일은 동물성, 식물성, 광물성 또는 합성오일로, 특히 수소화팜유, 수소화피마자유, 액체페트롤라텀, 액체파라핀, 푸르셀린유(purcellin oil), 휘발성 또는 비휘발성 실리콘유 그리고 이소파라핀에서 선택될 수 있다.
The fatty material may comprise oil or wax or mixtures thereof, fatty acids, fatty acid esters, fatty alcohols, petrolatum, paraffin, lanolin, hydrogenated lanolin or acetylated lanolin. Oils may be selected from animal, vegetable, mineral or synthetic oils, especially hydrogenated palm oil, hydrogenated castor oil, liquid petrolatum, liquid paraffin, purcellin oil, volatile or nonvolatile silicone oil and isoparaffin.
상기 선스크린용 화장료 조성물이 자외선으로부터 인체의 표피를 보호하기 위한 태양광선 차단 조성물인 경우, 용매나 지방 물질의 현탁액 또는 분산액의 형태를 취할 수 있으며, 또는 이와 달리 크림이나 유제 등의 에멀션(특히 수중유(oil-in-water, O/W) 또는 유중수(water-in-oil)형, 그러나 바람직하게는 O/W형, 또는 소포성(vesicle) 분산액의 형태, 혹은 연고, 젤, 고형 스틱 또는 에어로졸 거품의 형태를 취할 수 있다. 상기 에멀션은 추가로 음이온성, 비이온성, 양이온성 또는 양성 표면활성제를 포함할 수 있다.When the sunscreen cosmetic composition is a sunscreen composition for protecting the epidermis of a human body from ultraviolet rays, it may take the form of a suspension or dispersion of a solvent or a fatty substance, or alternatively may be an emulsion such as a cream or an emulsion In the form of oil-in-water or water-in-oil, but preferably in the form of O / W or vesicle dispersion, or ointments, gels, Or aerosol foam. The emulsion may further comprise anionic, nonionic, cationic or amphoteric surfactants.
또한, 상기 선스크린용 화장료 조성물을 모발보호용으로 사용하는 경우에는, 샴푸, 로션, 젤이나 또는 린스용 조성물의 형태로, 머리감기 전후, 염색 혹은 탈색(bleaching)전후, 웨이브퍼머 혹은 스트레이트 퍼머 동안이나 전후에 사용될 수 있고, 스타일링 혹은 트리트먼트용 로션이나 겔, 드라이어용 혹은 모발세터용 로션이나 겔, 헤어래커(hair lacquer)나 또는 모발의 웨이브 혹은 스트레이트퍼머용 조성물, 모발의 염색 혹은 탈색용 조성물의 형태를 취할 수가 있다.When the cosmetic composition for sunscreen is used for protecting hair, it may be formulated in the form of a composition for shampoo, lotion, gel or rinse, before, after, or after dyeing or bleaching, It can be used before and after, and it can be used for a lotion or gel for styling or treatment, a lotion or gel for hair dryer or hair setter, a composition for wave or straight permanent of hair lacquer or hair, Can take the form.
상기 선스크린용 화장료 조성물은 속눈썹, 눈썹, 피부 또는 모발용의 메이크업제품, 이를테면 피부치료용 크림, 파운데이션크림, 립스틱, 아이새도, 연지, 아이라이너, 마스카라 또는 착색겔(colouring gel)등으로 사용하는 경우에는, 고형물 또는 페이스트(paste)형 및 무수형 혹은 수성형, 이를테면 수중유(oil-in-water) 또는 유중수(water-in-oil) 에멀션, 현탁액 또는 겔일 수 있다.
The sunscreen cosmetic composition may be used for makeup products for eyelashes, eyebrows, skin or hair such as skin care creams, foundation creams, lipsticks, eye creams, lotions, eyeliners, mascaras or coloring gels In this case, it may be a solid or paste type and a water-free or water-forming, such as an oil-in-water or water-in-oil emulsion, a suspension or a gel.
본 발명은 또한, 상기 선스크린용 조성물을 포함하는 피부질환 치료제에 관한 것으로, 상기 피부 질환은 특별히 제한되지 않으나, 예를 들어 여드름, 건선, 탈모 또는 각질 이상 등일 수 있다.The present invention also relates to a skin disease treating agent comprising the composition for sunscreen. The skin disease is not particularly limited, but may be, for example, acne, psoriasis, hair loss or keratin deficiency.
더욱이, 본 발명은 상기 선스크린용 조성물을 포함하는 피부 외용제에 관한 것으로, 상기 피부 외용제는 피부 외부에서 도포되는 어떠한 것이라도 포함될 수 있는 총칭이며, 다양한 제형의 화장품, 의약품이 여기에 포함될 수 있다. 상기 피부 외용제는 또한, 특별히 제한되지 않으나, 예를 들어 피부 노화 방지용 또는 피부 주름 개선용 피부 외용제일 수 있다.
Further, the present invention relates to an external preparation for skin comprising the composition for sunscreen, wherein the external preparation for skin is a generic term including any substance applied outside the skin, and cosmetics and medicines of various formulations may be included. The external preparation for skin is not particularly limited, but may be, for example, a skin external preparation for preventing skin aging or improving skin wrinkles.
본 발명의 선스크린용 조성물은 신남산 유도체, 메톡시페닐아크릴레이트 유도체 및 β,β-디페닐아크릴레이트 유도체의 동시 존재로 광 조사시에 화학적 분해가 일어나지 않게 하여, 활성이 유지 및 상승되므로 광안정성(photo-stability)이 향상되어 광보호성이 우수하다. 그 결과 태양광 차단 효과가 뛰어난 조성물을 제공할 수 있다. 본 발명의 선스크린용 조성물은 상표명 'SolaWayTM'로 명명될 수 있다.The composition for a sunscreen according to the present invention does not cause chemical decomposition upon light irradiation due to the simultaneous presence of a cinnamic acid derivative, a methoxyphenyl acrylate derivative and a?,? - diphenylacrylate derivative, The photo-stability is improved and the optical protection is excellent. As a result, it is possible to provide a composition excellent in solar blocking effect. The composition for sunscreen according to the present invention may be named 'SolaWay TM '.
일반적으로 선스크린용으로 사용되는 트리아진 유도체 중의 하나인 Tinosorb S는, 최대함량 규제로 인해 우리나라와 유럽의 최대함량은 10% 이나, 일본의 경우 약 3% 이고, 더군다나 미국의 경우는 사용 허가가 아직 승인되지 않아 화장품에의 사용량이 법률적으로 제한된다. 따라서, Tinosorb S와 같은 특정 단일 성분이 단독적으로 많이 함유되어 야기되는 문제가 발생하지 않도록, 여러 성분들이 법적 규제의 내에서 문제가 없는 함량 범위만큼 포함되면서도, 우수한 광안정성을 달성할 수 있도록 하는 조합을 제공하는 것이다.
Tinosorb S, which is one of the triazine derivatives used for sunscreens in general, has a maximum content of 10% in Korea and Europe due to the maximum content regulation, and about 3% in Japan. Furthermore, in the case of the United States, It has not been approved yet and its usage in cosmetics is legally restricted. Therefore, in order to avoid problems caused by a single component such as Tinosorb S, various components may be included in a range that has a problem-free content within a legal regulation, .
이하의 실시를 통하여 본 발명이 더욱 상세하게 설명된다. 단, 실시예는 본 발명을 예시하기 위한 것으로서 이들만으로 본 발명의 범위가 한정되는 것은 아니다.
The present invention will be described in more detail through the following examples. However, the examples are for illustrating the present invention, and the scope of the present invention is not limited thereto.
[비교예 1][Comparative Example 1]
신남산 유도체로서 EHMC 6.00% 및 Neoheliopan E1000 3.00%와, 살리실산 유도체로서 Escalol 587 3.00%, 및 기타 조성물에 트리아진 유도체로서 비스-에틸헥실옥시페놀메톡시페닐트리아진(Tinosorb S, Ciba Specialty Chemicals社) 3.00%를 추가하여 수중유(oil-in-water, O/W) 형태로 제조하였으며, 오일 파트와 물 파트를 칭량하여 70℃에서 오일 파트를 물 파트에 투입, 균질화기(Homogenizer)로 3분간 6,000rpm에서 혼합하였다. 상기 기타 조성물은 하기와 같다. Ethylhexyloxyphenol methoxyphenyltriazine (Tinosorb S, Ciba Specialty Chemicals) as a triazine derivative as a derivative of cinnamic acid, 6.00% of EHMC, 3.00% of Neoheliopan E1000, 3.00% of Escalol 587 as a salicylic acid derivative, The oil part and the water part were weighed and added to the water part at 70 ° C and the mixture was homogenized for 3 minutes with a homogenizer And mixed at 6,000 rpm. The other compositions are as follows.
Abil EM90 2.00%, Bentone 38 1.50%, DC 345 3.00%, Finsolv TN 25.00%, 증류수 47.23%, EDTA.2Na 0.02%, NaCl 1.00%, Glycerin 5.00%, DM 0.20%, DP 0.05%
Bentone 38 1.50%, DC 345 3.00%, Finsolv TN 25.00%, distilled water 47.23%, EDTA.2Na 0.02%, NaCl 1.00%, Glycerin 5.00%, DM 0.20%, DP 0.05%
[비교예 2][Comparative Example 2]
상기 비교예 1에 사용된 물질 이외에, 에틸헥실메톡시크릴렌(Solarstay S1, Hallstar社)을 3.00% 추가하였고, Finsolv TN의 비율을 22.0%로 변경하였다. 기타 조성비 및 실시 방법은 상기 비교예 1과 동일하다.
In addition to the material used in Comparative Example 1, 3.00% of ethylhexylmethoxycrylyrene (Solarstay S1, Hallstar) was added and the ratio of Finsolv TN was changed to 22.0%. Other composition ratios and methods of implementation are the same as in Comparative Example 1 above.
[비교예 3][Comparative Example 3]
상기 비교예 1에 사용된 물질 이외에, 옥토크릴렌(Octocrylene, BASF社)을 3.00% 추가하였고, Finsolv TN의 비율을 22.0%로 변경하였다. 기타 조성비 및 실시 방법은 상기 비교예 1과 동일하다.
In addition to the material used in Comparative Example 1, 3.00% of octocrylene (BASF) was added, and the ratio of Finsolv TN was changed to 22.0%. Other composition ratios and methods of implementation are the same as in Comparative Example 1 above.
[실시예 1][Example 1]
상기 비교예 1에 사용된 물질 이외에, 에틸헥실메톡시크릴렌(Solarstay S1, Hallstar社) 2.50% 및 옥토크릴렌(Octocrylene, BASF社) 0.50%를 추가하였고, Finsolv TN의 비율을 22.0%로 변경하였다. 기타 조성비 및 실시 방법은 상기 비교예 1과 동일하다.
In addition to the materials used in Comparative Example 1, 2.50% of ethylhexylmethoxycrylene (Solarstay S1, Hallstar) and 0.50% of octocrylene (Octocrylene, BASF) were added, and the ratio of Finsolv TN was changed to 22.0% Respectively. Other composition ratios and methods of implementation are the same as in Comparative Example 1 above.
[실시예 2][Example 2]
상기 비교예 1에 사용된 물질 이외에, 에틸헥실메톡시크릴렌(Solarstay S1, Hallstar社) 2.00% 및 옥토크릴렌(Octocrylene, BASF社) 1.00%를 추가하였고, Finsolv TN의 비율을 22.0%로 변경하였다. 기타 조성비 및 실시 방법은 상기 비교예 1과 동일하다.
In addition to the materials used in Comparative Example 1, 2.00% of ethylhexylmethoxycyclylene (Solarstay S1, Hallstar) and 1.00% of octocrylene (Octocrylene, BASF) were added, and the ratio of Finsolv TN was changed to 22.0% Respectively. Other composition ratios and methods of implementation are the same as in Comparative Example 1 above.
[실시예 3][Example 3]
상기 비교예 1에 사용된 물질 이외에, 에틸헥실메톡시크릴렌(Solarstay S1, Hallstar社) 1.50% 및 옥토크릴렌(Octocrylene, BASF社) 1.50%를 추가하였고, Finsolv TN의 비율을 22.0%로 변경하였다. 기타 조성비 및 실시 방법은 상기 비교예 1과 동일하다.
In addition to the materials used in Comparative Example 1, 1.50% of ethylhexylmethoxycyclylene (Solarstay S1, Hallstar) and 1.50% of octocrylene (Octocrylene, BASF) were added, and the ratio of Finsolv TN was changed to 22.0% Respectively. Other composition ratios and methods of implementation are the same as in Comparative Example 1 above.
[실시예 4][Example 4]
상기 비교예 1에 사용된 물질 이외에, 에틸헥실메톡시크릴렌(Solarstay S1, Hallstar社) 1.00% 및 옥토크릴렌(Octocrylene, BASF社) 2.00%를 추가하였고, Finsolv TN의 비율을 22.0%로 변경하였다. 기타 조성비 및 실시 방법은 상기 비교예 1과 동일하다.
In addition to the materials used in Comparative Example 1, 1.00% of ethylhexylmethoxycircylene (Solarstay S1, Hallstar) and 2.00% of octocrylene (Octocrylene, BASF) were added, and the ratio of Finsolv TN was changed to 22.0% Respectively. Other composition ratios and methods of implementation are the same as in Comparative Example 1 above.
[실시예 5][Example 5]
상기 비교예 1에 사용된 물질 이외에, 에틸헥실메톡시크릴렌(Solarstay S1, Hallstar社) 0.50% 및 옥토크릴렌(Octocrylene, BASF社) 2.50%를 추가하였고, Finsolv TN의 비율을 22.0%로 변경하였다. 기타 조성비 및 실시 방법은 상기 비교예 1과 동일하다.
In addition to the materials used in Comparative Example 1, 0.50% of ethylhexylmethoxycrylene (Solarstay S1, Hallstar) and 2.50% of octocrylene (Octocrylene, BASF) were added, and the ratio of Finsolv TN was changed to 22.0% Respectively. Other composition ratios and methods of implementation are the same as in Comparative Example 1 above.
[실시예 6][Example 6]
상기 비교예 1에 사용된 물질 이외에, 에틸헥실메톡시크릴렌(Solarstay S1, Hallstar社) 1.00%, 옥토크릴렌(Octocrylene, BASF社) 1.00% 및 폴리실리콘-15(Polysilicone-15, DSM社) 1.00%를 추가하였고, Finsolv TN의 비율을 22.0%로 변경하였다. 기타 조성비 및 실시 방법은 상기 비교예 1과 동일하다.
1.00% of ethylhexylmethoxycrylylene (Solarstay S1, Hallstar), 1.00% of octocrylene (BASF) and polysilicon-15 (Polysilicone-15, DSM) 1.00%, and the ratio of Finsolv TN was changed to 22.0%. Other composition ratios and methods of implementation are the same as in Comparative Example 1 above.
[실험예 1] 광량에 따른 광안정도 측정[Experimental Example 1] Measurement of light intensity according to light quantity
상기 비교예 1 내지 3 및 실시예 1 내지 6에 따른 조성물에 관하여 광량에 따른 광안정도(photo-stability)를 측정하였다. UV 스펙트럼(290nm~400nm)은 제논광을 사용하였고, 선택적으로, 국제적으로 인체실험에 사용되는 인증된 기기인 UV영역을 통과시키는 필터를 장착한 601 Multiport® solar simulator(Solar Light company inc., USA)를 사용하였다. The photo-stability of the compositions according to Comparative Examples 1 to 3 and Examples 1 to 6 was measured according to the amount of light. The UV spectra (290 nm to 400 nm) used xenon light and, optionally, the 601 Multiport ® solar simulator (Solar Light company inc., USA) equipped with a filter to pass UV region, a certified device used internationally in human experiments ) Was used.
Quartz, PMMA, VitroSkin의 기질에 0.5 내지 2mg/㎠ 의 양으로 각 실시예 및 비교예를 도포한 후 상기 조사 기기를 이용하여 10MED, 25MED, 50MED의 광량에서 실시하였다. 각각의 광안정도 측정은 분광광도계(Spectrophotometer)인 SPF-290S analyzer (Optometrics corp., UK)를 이용하였다. 그 결과는 하기 표 2와 같다.
Quartz, PMMA, and VitroSkin were applied to the substrates in an amount of 0.5 to 2 mg / cm 2, and then irradiated with 10MED, 25MED, and 50MED using the irradiation apparatus. The SPF-290S analyzer (Optometrics corp., UK) was used as a spectrophotometer. The results are shown in Table 2 below.
solarstay 2.5%Octocrylene 0.5%
solarstay 2.5%
solarstay 2%Octocrylene 1%
solarstay 2%
solarstay 1.5%Octocrylene 1.5%
solarstay 1.5%
solarstay 1%Octocrylene 2%
solarstay 1%
solarstay 0.5%Octocrylene 2.5%
solarstay 0.5%
solarstay 1.0%
polysilicone-15 1.0%Octocrylene 1.0%
solarstay 1.0%
polysilicone-15 1.0%
상기 표 2에서 확인할 수 있듯이, EHMC 6.00%, Neoheliopan E1000 3.00%, Escalol 587 3.00% 외에, 비교예 1 내지 3에서 Tinosorb S 하나만, 또는 Tinosorb S와 Solarstay, 또는 Tinosorb S와 Octocrylene와 같이 두 가지를 동시에 사용한 경우에 비하여, Tinosorb S, Solarstay, Octocrylene 세 가지를 동시에 포함하였을 때 광안정도가 우수하였다.As shown in the above Table 2, in addition to 6.00% of EHMC, 3.00% of Neoheliopan E1000, 3.00% of Escalol 587, and Tinosorb S in Comparative Examples 1 to 3, or Tinosorb S and Solarstay, or Tinosorb S and Octocrylene, Compared to the case of using Tinosorb S, Solarstay and Octocrylene,
즉, 조성물이 신남산 유도체, 트리아진 유도체, 메톡시페닐아크릴레이트 및 β,β-디페닐아크릴레이트 유도체를 동시에 포함하는 경우, 광안정도가 개선되어 광보호성이 뛰어남을 알 수 있다. That is, when the composition contains a cinnamic acid derivative, a triazine derivative, methoxyphenyl acrylate and a?,? - diphenylacrylate derivative at the same time, the photostability is improved and the photoprotective property is excellent.
Claims (11)
상기 조성물은 광안정성 및 광보호성을 갖는 것인 선스크린용 조성물.
A cinnamic acid derivative, a methoxyphenyl acrylate derivative and a?,? - diphenylacrylate derivative as an active ingredient,
Wherein the composition has a light stability and an optical protection property.
상기 메톡시페닐아크릴레이트 유도체는 에틸헥실메톡시크릴렌인 선스크린용 조성물.
The method according to claim 1,
Wherein the methoxyphenylacrylate derivative is ethylhexylmethoxycrylene.
상기 β,β-디페닐아크릴레이트 유도체는 옥토크릴렌 또는 에토크릴렌, 또는 그 둘 다인 선스크린용 조성물.
The method according to claim 1,
Wherein the beta, beta -diphenylacrylate derivative is octocrylene or ethocrylene, or both.
상기 조성물은 트리아진 유도체를 더 포함하는 선스크린용 조성물.
The method according to claim 1,
Wherein the composition further comprises a triazine derivative.
상기 조성물은 살리실산 유도체를 더 포함하는 선스크린용 조성물.
The method according to claim 1,
Wherein the composition further comprises a salicylic acid derivative.
상기 조성물은 벤잘말로네이트 유도체를 더 포함하는 선스크린용 조성물.
The method according to claim 1,
Wherein the composition further comprises a benzal malonate derivative.
상기 신남산 유도체는 2-에틸헥실 p-메톡시신나메이트, 이소아밀 p-메톡시신나메이트, 이소프로필 메톡시신나메이트, 이소펜틸 메톡시신나메이트, 디이소프로필 메틸신나메이트, 디에탄올아민 메톡시신나메이트, 시녹세이트 및 글리세릴 에틸헥사노에이트 디메톡시신나메이트로 이루어진 군으로부터 선택되는 하나 이상인 것인 선스크린용 조성물.
The method according to claim 1,
The cinnamic acid derivatives include 2-ethylhexyl p-methoxy cinnamate, isoamyl p-methoxy cinnamate, isopropyl methoxy cinnamate, isopentyl methoxy cinnamate, diisopropyl methyl cinnamate, diethanolamine meth Wherein the composition is at least one selected from the group consisting of sodium methoxide, sodium ethoxide, cinnamate, and glyceryl ethylhexanoate dimethoxy cinnamate.
상기 트리아진 유도체는 비스-에틸헥실옥시페놀메톡시페닐트리아진 또는 트리스(디이소부틸-아미노벤잘말로네이트)트리아진, 또는 그 둘 다인 선스크린용 조성물.
5. The method of claim 4,
Wherein the triazine derivative is bis-ethylhexyloxyphenol methoxyphenyltriazine or tris (diisobutyl-aminobenzalmalonate) triazine, or both.
상기 살리실산 유도체는 2-에틸헥실 살리실레이트, 호모멘틸 살리실레이트, 트리에탄올아민 살리실레이트, 이소프로필벤질 살리실레이트, 디프로필렌글리콜 살리실레이트 및 옥틸 살리실레이트로 이루어진 군으로부터 선택되는 하나 이상 것인 선스크린용 조성물.
6. The method of claim 5,
Wherein the salicylic acid derivative is at least one selected from the group consisting of 2-ethylhexyl salicylate, homomenthyl salicylate, triethanolamine salicylate, isopropylbenzyl salicylate, dipropylene glycol salicylate and octyl salicylate. ≪ / RTI >
상기 벤잘말로네이트 유도체는 폴리실리콘-15인 선스크린용 조성물.
The method according to claim 6,
Wherein the benzal malonate derivative is polysilicon-15.
상기 조성물은 UV-A, UV-B, 또는 UV-A 및 UV-B에 활성인 부가의 친수성 또는 친유성 광차단제를 추가로 함유하는 것인 선스크린용 조성물.11. The method according to any one of claims 1 to 10,
Wherein the composition further comprises additional hydrophilic or lipophilic light-blocking agents active in UV-A, UV-B, or UV-A and UV-B.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100116411A KR101753655B1 (en) | 2010-11-22 | 2010-11-22 | Composition for sunscreen |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100116411A KR101753655B1 (en) | 2010-11-22 | 2010-11-22 | Composition for sunscreen |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20120058688A KR20120058688A (en) | 2012-06-08 |
KR101753655B1 true KR101753655B1 (en) | 2017-07-06 |
Family
ID=46610125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020100116411A KR101753655B1 (en) | 2010-11-22 | 2010-11-22 | Composition for sunscreen |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101753655B1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090291141A1 (en) * | 2007-08-09 | 2009-11-26 | Hallstar Innovations Corp. | Method of quenching electronic excitation of chromophore-containing organic molecules in photoactive compositions |
-
2010
- 2010-11-22 KR KR1020100116411A patent/KR101753655B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090291141A1 (en) * | 2007-08-09 | 2009-11-26 | Hallstar Innovations Corp. | Method of quenching electronic excitation of chromophore-containing organic molecules in photoactive compositions |
Also Published As
Publication number | Publication date |
---|---|
KR20120058688A (en) | 2012-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017239521B2 (en) | Novel photoprotective system | |
JP5722319B2 (en) | Combinations of UV filters containing benzylidene malonates | |
CN111867551A (en) | Cosmetic composition for cutting ultraviolet rays, having ultraviolet ray cutting efficiency increased by ultraviolet rays | |
CA2231080A1 (en) | Concentrated solutions of a 1,3,5-triazine derivative sunscreen and their use for the preparation of cosmetic compositions | |
KR20000022115A (en) | Compositions containing 4-tert-butyl-4'-methoxy-dibenzoylmethane, a 1,3,5-triazine derivative and an alkyl (a-cyano)-beta,beta'-diphenylacrylate and uses | |
TWI645859B (en) | Composition and composition of BMDEM (butyl methoxybenzhydrylmethane) light stabilizer and sunscreen | |
EP0850935A2 (en) | Concentrated solutions of a 1,3,5-triazine derivative sunscreen and their use for the preparation of cosmetic compositions | |
EP0821941A1 (en) | Sun screening preparations comprising triazine derivatives | |
JP3893336B2 (en) | Shielding composition containing benzoylmethane derivative and 1,1,3-tris (2-methyl-4-hydroxy-5-tert-butylphenyl) butane | |
KR101753655B1 (en) | Composition for sunscreen | |
KR101767206B1 (en) | Composition for screening light | |
EP0821938A1 (en) | Sun screening preparations comprising triazine derivatives | |
EP0821939A1 (en) | Sun screening preparations comprising triazine derivatives | |
EP0821937A1 (en) | Sun screening preparations comprising triazine derivatives | |
KR20130014151A (en) | Uv protecting cosmetic composition containg kaempferitrin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right |